carbostyril has been researched along with Metabolic Syndrome in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (44.44) | 29.6817 |
| 2010's | 9 (50.00) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Che, KK; Hu, CH; Li, DJ; Liu, L; Liu, XM; Yue, Q | 1 |
| Byerly, MJ; Glick, ID; Hamer, RM; Khan, AY; Lamberti, JS; McEvoy, JP; Nasrallah, HA; Ray, N; Steinbook, RM; Stroup, TS | 1 |
| Kusnir, D; LoPiccolo, M; Sandoz, A; Tausk, FA | 1 |
| Perini, GI; Pigato, G; Toffanin, T | 1 |
| Baker, RA; Kim, E; Meyer, JM; Rosenblatt, LC; Whitehead, R | 1 |
| Baker, RA; Calabrese, JR; Eudicone, JM; Kemp, DE; Pikalov, A; Tran, QV | 1 |
| Kozumplik, O; Sedić, B; Uzun, S | 1 |
| Baker, RA; Chambers, JS; Eudicone, JM; Kemp, DE; McQuade, RD | 1 |
| Ahn, YM; Jung, DC; Kang, UG; Kim, EY; Kim, SH; Kim, YS; Lee, NY; Sung, KH; Yu, HY | 1 |
| Basu, R; Brar, JS; Chang, CC; Ganguli, R; Garbut, R | 1 |
| Arndt, S; Glorioso, DK; Golshan, S; Henry, R; Jeste, DV; Jin, H; Kraemer, HC; Mudaliar, S; Shih, PA | 1 |
| Baker, RA; Carlson, BX; De Hert, M; Eudicone, JM; Fyans, P; Kemp, DE; Marler, SV; Rahman, Z | 1 |
| Ananjit, S; Badiah, Y; Bulgiba, A; Habil, MH; Hairi, NN; Haslina, MY; Hatim, A; Mahmud, B; Ramli, MA; Said, MA; Sapini, Y; Shah, M; Zafidah, W | 1 |
| Kerpel-Fronius, S; Lóránt, M | 1 |
| De Hert, M; Hanssens, L; Peuskens, J; Scheen, A; Van Eyck, D; van Winkel, R; Wampers, M | 1 |
| Correll, CU; Frederickson, AM; Kane, JM; Manu, P | 1 |
| Thomas, P | 1 |
| Carson, WH; Casey, DE; Kan, HJ; L'Italien, GJ; Marcus, RN | 1 |
3 review(s) available for carbostyril and Metabolic Syndrome
| Article | Year |
|---|---|
A clinical paradigm of delusions of parasitosis.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Diagnosis, Differential; Female; Humans; Metabolic Syndrome; Middle Aged; Olanzapine; Pain; Patient Compliance; Peripheral Nervous System Diseases; Piperazines; Quinolones; Schizophrenia, Paranoid; Skin Diseases, Parasitic; Sleep Wake Disorders | 2008 |
[A new atypical antipsychotic with partial dopamine agonist effect (aripiprazole)].
Topics: Antipsychotic Agents; Aripiprazole; Controlled Clinical Trials as Topic; Dopamine Agonists; Evidence-Based Medicine; Humans; Meta-Analysis as Topic; Metabolic Syndrome; Piperazines; Quinolones; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists | 2004 |
The stable patient with schizophrenia--from antipsychotic effectiveness to adherence.
Topics: Antipsychotic Agents; Aripiprazole; Chronic Disease; Humans; Metabolic Syndrome; Patient Compliance; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology | 2007 |
5 trial(s) available for carbostyril and Metabolic Syndrome
| Article | Year |
|---|---|
Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Coronary Artery Disease; Dibenzothiazepines; Drug Substitution; Female; Humans; Longitudinal Studies; Male; Metabolic Syndrome; Middle Aged; Multicenter Studies as Topic; Odds Ratio; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone | 2013 |
Metabolic syndrome in patients enrolled in a clinical trial of aripiprazole in the maintenance treatment of bipolar I disorder: a post hoc analysis of a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Antipsychotic Agents; Argentina; Aripiprazole; Bipolar Disorder; Comorbidity; Cross-Sectional Studies; Double-Blind Method; Female; Humans; Incidence; Long-Term Care; Male; Metabolic Syndrome; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones | 2010 |
Changes in weight and other metabolic indicators in persons with schizophrenia following a switch to aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Cardiovascular Diseases; Drug Substitution; Female; Humans; Male; Metabolic Syndrome; Middle Aged; Overweight; Piperazines; Quinolones; Schizophrenia; Weight Loss | 2011 |
Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol; Dibenzothiazepines; Female; Follow-Up Studies; Humans; Male; Metabolic Syndrome; Middle Aged; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Therapeutic Equipoise; Triglycerides; United States | 2013 |
Investigation into the long-term metabolic effects of aripiprazole adjunctive to lithium, valproate, or lamotrigine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lamotrigine; Lithium; Male; Metabolic Syndrome; Middle Aged; Obesity; Overweight; Piperazines; Quinolones; Time Factors; Treatment Outcome; Triazines; Valproic Acid | 2013 |
10 other study(ies) available for carbostyril and Metabolic Syndrome
| Article | Year |
|---|---|
Brexpiprazole caused glycolipid metabolic disorder by inhibiting GLP1/GLP1R signaling in rats.
Topics: Animals; Blood Glucose; Body Weight; Down-Regulation; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Insulin; Insulin Resistance; Intestine, Small; Liraglutide; Liver; Male; Metabolic Syndrome; Muscle, Skeletal; Pancreas; Quinolones; Rats; Signal Transduction; Thiophenes | 2021 |
Is a high dosage aripiprazole-clozapine combination an effective strategy for treatment-resistant schizophrenic patients? A case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Resistance; Drug Therapy, Combination; Humans; Male; Metabolic Syndrome; Piperazines; Quinolones; Schizophrenia, Paranoid | 2009 |
The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Black or African American; Blood Glucose; Body Weight; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Hispanic or Latino; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Obesity; Olanzapine; Piperazines; Quinolones; Randomized Controlled Trials as Topic; White People; Young Adult | 2009 |
Changes in values of cholesterol and tryglicerides after weight loss during treatment with aripiprazole in a patient with schizophrenia - Case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cholesterol; Croatia; Dose-Response Relationship, Drug; Feeding Behavior; Humans; Life Style; Male; Metabolic Syndrome; Piperazines; Quinolones; Schizophrenia; Triglycerides; Weight Loss | 2010 |
Metabolic syndrome and its potential effect on treatment response to aripiprazole: a post hoc analysis of the stabilization phase of a long-term, double-blind study in patients with bipolar disorder (CN138-010).
Topics: Aripiprazole; Bipolar Disorder; Double-Blind Method; Humans; Metabolic Syndrome; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2010 |
The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving a monotherapy with aripiprazole, olanzapine or risperidone.
Topics: Adult; Age Factors; Antipsychotic Agents; Aripiprazole; Asian People; Benzodiazepines; Cohort Studies; Databases, Factual; Female; Hospitals, University; Humans; Male; Medical Records; Metabolic Syndrome; Middle Aged; Olanzapine; Piperazines; Quinolones; Republic of Korea; Retrospective Studies; Risperidone; Schizophrenia; Sex Factors; Young Adult | 2011 |
Metabolic syndrome and antipsychotic monotherapy treatment among schizophrenia patients in Malaysia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Cross-Sectional Studies; Female; Flupenthixol; Humans; Malaysia; Male; Metabolic Syndrome; Middle Aged; Piperazines; Quinolones; Schizophrenia; Trifluoperazine; Waist Circumference; Young Adult | 2013 |
A case series: evaluation of the metabolic safety of aripiprazole.
Topics: Adult; Anthropometry; Antipsychotic Agents; Aripiprazole; Belgium; Cohort Studies; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Follow-Up Studies; Glucose Tolerance Test; Humans; Insulin Resistance; Lipids; Male; Mass Screening; Metabolic Syndrome; Middle Aged; Piperazines; Prospective Studies; Quinolones; Schizophrenia; Sex Factors; Treatment Outcome | 2007 |
Does antipsychotic polypharmacy increase the risk for metabolic syndrome?
Topics: Adult; Age Factors; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Mass Index; Cholesterol, HDL; Clozapine; Cross-Sectional Studies; Dibenzothiazepines; Drug Therapy, Combination; Female; Humans; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Piperazines; Quetiapine Fumarate; Quinolones; Risk Factors; Schizophrenia; Thiazoles; Triglycerides | 2007 |
Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo.
Topics: Acute Disease; Adult; Anthropometry; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cholesterol, HDL; Drug Administration Schedule; Female; Humans; Hyperlipidemias; Hypertension; Incidence; Male; Metabolic Syndrome; Olanzapine; Piperazines; Prevalence; Quinolones; Schizophrenia | 2007 |